Literature DB >> 11536171

Inflamed kidneys of NZB / W mice are a major site for the homeostasis of plasma cells.

G Cassese1, S Lindenau, B de Boer, S Arce, A Hauser, G Riemekasten, C Berek, F Hiepe, V Krenn, A Radbruch, R A Manz.   

Abstract

(NZB x NZW)F1 (NZB / W) mice develop a disease similar to human systemic lupus erythematosus (SLE), including autoantibody production, hypergammaglobulinaemia and inflammation of the kidneys. It is known that large numbers of lymphocytes infiltrate the kidneys of these mice. Here, we compare the roles of bone marrow, spleen and inflamed kidneys of NZB / W mice in the activation of B cells and the persistence of antibody-secreting cells (ASC). ASC are present in the kidneys of NZB / W mice with full-blown disease, as many as in the spleen and bone marrow. The specificity of the ASC in the inflamed kidneys is not restricted to self-antigens. After immunization of NZB / W mice with ovalbumin (OVA) the OVA-specific ASC are found initially in the spleen. Weeks later, OVA-specific ASC are found in high numbers in the bone marrow and the kidneys of these mice, but no longer in the spleen. As determined by FACS, B cells with a germinal center phenotype (B220(+) / PNA(+)) are found only in very low numbers in the kidneys, but in high numbers in the spleen of NZB / W mice. Germinal centers could not be detected in the kidneys, but in the spleen, and plasma cells appear to be scattered over the tissue. These data suggest that in autoimmune NZB / W mice, plasma cells generated in immune reactions of secondary lymphoid organs, later accumulate and persist in the inflamed kidneys, were they enhance the local concentrations of Ab and immunocomplexes. These experiments identify the inflamed kidneys of NZB / W mice as a site of prime relevance for the homeostasis of plasma cells, irrespective of their specificity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11536171     DOI: 10.1002/1521-4141(200109)31:9<2726::aid-immu2726>3.0.co;2-h

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  79 in total

1.  Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease.

Authors:  M Youd; C Blickarz; L Woodworth; T Touzjian; A Edling; J Tedstone; M Ruzek; R Tubo; J Kaplan; T Lodie
Journal:  Clin Exp Immunol       Date:  2010-04-29       Impact factor: 4.330

Review 2.  Control systems and decision making for antibody production.

Authors:  Christopher C Goodnow; Carola G Vinuesa; Katrina L Randall; Fabienne Mackay; Robert Brink
Journal:  Nat Immunol       Date:  2010-07-20       Impact factor: 25.606

3.  In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis.

Authors:  Anthony Chang; Scott G Henderson; Daniel Brandt; Ni Liu; Riteesha Guttikonda; Christine Hsieh; Natasha Kaverina; Tammy O Utset; Shane M Meehan; Richard J Quigg; Eric Meffre; Marcus R Clark
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

Review 4.  [Autoantibodies and antibody-secreting cells].

Authors:  F Hiepe; T Dörner
Journal:  Z Rheumatol       Date:  2005-09       Impact factor: 1.372

Review 5.  Long-lived autoreactive plasma cells drive persistent autoimmune inflammation.

Authors:  Falk Hiepe; Thomas Dörner; Anja E Hauser; Bimba F Hoyer; Henrik Mei; Andreas Radbruch
Journal:  Nat Rev Rheumatol       Date:  2011-02-01       Impact factor: 20.543

Review 6.  B cells in glomerulonephritis: focus on lupus nephritis.

Authors:  Menna R Clatworthy; Kenneth G C Smith
Journal:  Semin Immunopathol       Date:  2007-10-18       Impact factor: 9.623

7.  B cell proliferation, somatic hypermutation, class switch recombination, and autoantibody production in ectopic lymphoid tissue in murine lupus.

Authors:  Dina C Nacionales; Jason S Weinstein; Xiao-Jie Yan; Emilia Albesiano; Pui Y Lee; Kindra M Kelly-Scumpia; Robert Lyons; Minoru Satoh; Nicholas Chiorazzi; Westley H Reeves
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

8.  T cell reactivity against the SmD1(83-119) C terminal peptide in patients with systemic lupus erythematosus.

Authors:  G Riemekasten; C Weiss; S Schneider; A Thiel; A Bruns; F Schumann; S Bläss; G-R Burmester; F Hiepe
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

Review 9.  The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease.

Authors:  Brian P O'Connor; Michael W Gleeson; Randolph J Noelle; Loren D Erickson
Journal:  Immunol Rev       Date:  2003-08       Impact factor: 12.988

Review 10.  The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis.

Authors:  Marcus R Clark; Kimberly Trotter; Anthony Chang
Journal:  Semin Nephrol       Date:  2015-09       Impact factor: 5.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.